News Detail
BOSTON, 30 APRIL 2024 (GLOBE NEWSWIRE) X4 Pharmaceuticals View Details
Source : GLOBE NEWSWIRE
X4 Pharmaceuticals
XOLREMDIâ„¢ (mavorixafor)
WHIM syndrome (warts
hypogammaglobulinemia
infections and myelokathexis)
U.S. Food and Drug Administration (FDA)
Related News
- Fake degrees seized from pvt institute in Hisar (13-12-2024)
- Health ministry assign testing labs for surgical and medical examination gloves (13-12-2024)
- DCGI asks States to approve all applications for medicines and medical devices for rare diseases within three months (13-12-2024)
- Karnataka to restructure drugs control dept, strengthen procedures (13-12-2024)
- US FDA identifies cases of liver injury after treatment with Intercept's Ocaliva (obeticholic acid) (13-12-2024)
- Fake platelets sold for 15 thousand rupees in Prayagraj, CMO ordered an inquiry (12-12-2024)
- Cardiac drug sales signal increase in heart ailments (12-12-2024)
- Banned cough syrup worth Rs 15 lakh seized, driver arrested (12-12-2024)
- Sales in the respiratory market reached Rs 1,638 crore in November 2024 (12-12-2024)
- Kenya Govt Cautions Kenyans after Unregistered Cancer Drug Hits Market (12-12-2024)